BRIP1 and ovarian cancer: While biallelic loss of function causes Fanconi anemia, heterozygous carriers of pathogenic BRIP1 variants have been shown to face an increased susceptibility to ovarian cancer, with lifetime risks by age 80 estimated at approximately 4–9% [40, 41].